 |
 |
|
|
RESÚMENES OCTUBRE 2005 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Evaluation
of the clinical efficacy of risperidone for untreated and treated cases of
schizophrenia from various aspects
Himei A, Okamura T
Psychiatry Clin Neurosci.
2005 Oct;59(5):556-62
Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis
Diana O. Perkins, Hongbin Gu, Kalina Boteva, and Jeffrey A. Lieberman
Am J Psychiatry 162:1785-1804, October 2005
Duration of Untreated Psychosis and Time to Treatment Response for Delusions and Hallucinations
Handan Gunduz-Bruce, Marjorie McMeniman, Delbert G. Robinson, Margaret
G. Woerner, John M. Kane, Nina R. Schooler, Jeffrey A. Lieberman
Am J Psychiatry 162:1966-1969, October 2005
Morphology of the Anterior Cingulate Gyrus in Patients With Schizophrenia: Relationship to Typical Neuroleptic Exposure
Alison Kopelman, Nancy C. Andreasen, and Peg Nopoulos
Am J Psychiatry
162:1872-1878, October 2005
Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia
Alan Breier, Paul H. Berg, Jogin H. Thakore, Dieter Naber, Wagner F.
Gattaz, Patrizia Cavazzoni, Daniel J. Walker, Suraja M. Roychowdhury, and John
M. Kane
Am J Psychiatry
162:1879-1887, October 2005
Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial
Philip D. Harvey, Jonathan Rabinowitz, Marielle Eerdekens, and Michael
Davidson
Am J Psychiatry
162:1888-1895, October 2005
High
homocysteine serum levels in young male schizophrenia and bipolar patients and
in an animal model
Joseph Levine,
Ben-Ami Sela, Yamima Osher and R.H. Belmaker
Perminder S. Sachdev
Progress
in Neuro-Psychopharmacology and Biological Psychiatry. Volume 29, Issue 7,
September 2005, Pages 1152-1161
Aberrant
folate status in schizophrenic patients: What is the evidence?
Jan-Willem
Muntjewerff and Henk J. Blom
STEFAN LEUCHT, JOHN M. KANE, WERNER KISSLING, JOHANNES HAMANN, EVA
ETSCHEL, ROLF ENGEL
The British Journal of Psychiatry (2005) 187: 366-371
MICHAEL J. GOLDACRE, LIANNE M. KURINA, CLARE J. WOTTON, DAVID YEATES,
VALERIE SEAGROAT
The British Journal of Psychiatry (2005) 187: 334-338
BOB GREEN, ROSS YOUNG, DAVID KAVANAGH
The British Journal of Psychiatry (2005) 187: 306-313
Nigel M Williams, Michael C O'Donovan, Michael J Owen
Schizophrenia Bulletin 2005
31(4):800-805
A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICS Project
Elizabeth Bromley
Schizophrenia Bulletin 2005
31(4):954-961
Igor Bombin, Celso Arango, Robert W Buchanan
Schizophrenia Bulletin 2005
31(4):962-977
Enhanced 5-HT2C receptor signaling is associated with
haloperidol-induced “early onset” vacuous chewing in rats: implications for
antipsychotic drug therapy
William A. Wolf,
Gerald J. Bieganski, Veronica Guillen and Laurence Mignon
Psychopharmacology 2005; Volume 182, Number 1: 84
- 94
Cigarette smoking
topography in smokers with schizophrenia and matched non-psychiatric controls
Jennifer W. Tidey,
Damaris J. Rohsenow, Gary B. Kaplan and Robert M. Swift
Drug and Alcohol Dependence. Volume 80, Issue 2, 1
November 2005, Pages 259-265
A
randomized double-blind 12-week study of quetiapine, risperidone or
fluphenazine on sexual functioning in people with schizophrenia
Kelly DL, Conley RR
Psychoneuroendocrinology. 2005 Sep 27; [Epub ahead of
print]
Benno G. Schimmelmann,
Philippe Conus, Jane Edwards, Patrick D. McGorry, and Martin Lambert
J Clin Psychiatry 2005;66:1239-1246
Therapeutic
drug monitoring of patients on risperidone depot
Nesvag R, Tanum L
Nord J Psychiatry. 2005;59(1):51-5
Volume increases
in striatum associated with positive symptom reduction in schizophrenia: A
preliminary observation
Stephen Taylor,
James D. Christensen, Jennifer M. Holcomb and David L. Garver
Psychiatry Research: Neuroimaging. Volume 140, Issue
1, 30 October 2005, Pages 85-89
Clinical
course of acute poisoning with olanzapine
Balicka-Slusarczyk B,
Szczeklik J, Szpak D, Groszek B
Nocturnal
hormone profiles in patients with schizophrenia treated with olanzapine
Mann K, Rossbach W, Muller
MJ, Muller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C
Psychoneuroendocrinology. 2005 Sep 23; [Epub ahead of
print]
Comparative
efficacy of antipsychotics in the treatment of schizophrenia: A critical
assessment
Rajiv Tandon and W.
Wolfgang Fleischhacker
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 145-155
Variations in
myelin and oligodendrocyte-related gene expression across multiple brain
regions in schizophrenia: A gene ontology study
Pavel Katsel,
Kenneth L. Davis and Vahram Haroutunian
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 157-173
Regional striatal
volume abnormalities in schizophrenia: Effects of comorbidity for alcoholism,
recency of alcoholic drinking, and antipsychotic medication type
Anjali Deshmukh,
Margaret J. Rosenbloom, Eve De Rosa, Edith V. Sullivan and Adolf Pfefferbaum
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 189-200
Paolo Brambilla,
Roberto Cerini, Anna Gasparini, Amelia Versace, Nicola Andreone, Enrico
Vittorini, Corrado Barbui, Luisa Pelizza, Michela Nosè, Leone Barlocco,
Giovanna Marrella, Manuela Gregis, Kalliopi Tournikioti, Antony S. David,
Matcheri S. Keshavan and Michele Tansella
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 201-210
The underlying
structure of diagnostic systems of schizophrenia: A comprehensive
polydiagnostic approach
Victor Peralta and
Manuel J. Cuesta
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 217-229
Improvement of
extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration
in antipsychotic treated schizophrenia patients: A randomized, double-blind
placebo controlled trial
Tali Nachshoni,
Tanya Ebert, Yehuda Abramovitch, Miriam Assael-Amir, Moshe Kotler, Rachel
Maayan, Abraham Weizman and Rael D. Strous
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 251-256
Lori P. Montross,
Concepcion Barrio, Ann-Marie Yamada, Laurie Lindamer, Shahrokh Golshan, Piedad
Garcia, Dahlia Fuentes, Rebecca E. Daly, Richard L. Hough and Dilip V. Jeste
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 297-305
The association of
fetal and childhood growth with risk of schizophrenia. Cohort study of 720,000
Swedish men and women
D. Gunnell, G.
Harrison, E. Whitley, G. Lewis, P. Tynelius and F. Rasmussen
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 315-322
Increased nicotine
and cotinine levels in smokers with schizophrenia and schizoaffective disorder
is not a metabolic effect
Jill M. Williams,
Douglas M. Ziedonis, Francisca Abanyie, Marc L. Steinberg, Jonathan Foulds and
Neal L. Benowitz
Schizophrenia
Research. Volume 79, Issues 2-3, 15 November 2005, Pages 323-335
A retrospective
comparison of cumulative time spent in remission during treatment with
olanzapine or risperidone among patients with schizophrenia
Gopalan Sethuraman,
Cindy C. Taylor, Mark Enerson and Eduardo Dunayevich
Schizophrenia Research. Volume 79, Issues 2-3, 15 November 2005, Pages 337-340
Nutritional
intervention to prevent weight gain in patients commenced on olanzapine: a
randomized controlled trial
Evans S, Newton R, Higgins
S
Aust N Z J Psychiatry. 2005 Jun;39(6):479-86
A
crossover study on lipid and weight changes associated with olanzapine and
risperidone
Su KP, Wu PL, Pariante CM
Psychopharmacology (Berl). 2005 Oct 21;:1-4 [Epub
ahead of print]
Cigdem Aydemir,
Erol Goka, Cebrail Kisa, Aydin Kurt, Fatih Volkan Yuksel
Olanzapine in subjects with a first-episode
psychosis non-responsive, intolerant or non-compliant to a first-line trial of
risperidone
Martin Lambert,
Philippe Conus, Dieter Naber, Patrick D Mcgorry, Benno Graf Schimmelmann
Mathias Zink